Since SB202190 reduces p-Akt signaling, this off-target effect, along with p38 and Erk1-2 inhibition in BRAF-mutated CRC organoids, could be the first step for the development of new multitarget drugs. This evidence concerns the gene AKT1 and colorectal carcinoma.